Rising health care costs are driving many policy conversations, and prescription drug pricing is no exception. Sameer Awsare, MD, associate executive director, The Permanente Medical Group, joined other experts invited by the Alliance for Health Policy for a web event…
Physician leader Sameer Awsare, MD, FACP, co-writes an article in Health Affairs encouraging competition in the biosimilar drugs market to help curb rising health care costs.
Presenting at this week’s GRx+Biosims meeting in North Bethesda, Maryland, Sameer Awsare, MD, an associate executive director of The Permanente Medical Group, elaborated on how Kaiser Permanente leverages its integrated care model to drive collaboration in advancing the move to biosimilars.
The U.S. Chamber of Commerce hosted its 2019 Health Care Summit, "The Business of Health: Transforming with Transparency," in Washington, D.C. on Thursday, October 31.
Sameer Awsare, MD, FACP, focuses on government rules and state laws attempting to hold pharmaceutical companies accountable to escalating prescription drug prices, and asks what's true transparency?
This first podcast for 2019 includes Permanente physician leaders’ insights and best practices on tackling the epidemic of opioid abuse and addiction.
During a public briefing at the Alliance for Health Policy, Sameer Awsare, MD, of The Permanente Medical Group, joined other health care leaders to explain the mechanisms of biosimilar drugs.
Sameer Awsare, MD, associate executive director at The Permanente Medical Group, addresses the need to curb prices on biologics to protect patients.
New ACHP research reveals five strategies that speed medical evidence from lab to exam room, and improve patient outcomes.
The Permanente Medical Groups utilize a four-pronged approach to prescription opioids that focuses on physician education, community protection, patient safety, and patient education.